Halozyme (HALO) on CMS IPAY 2028 guidance, Part B projections
Halozyme Therapeutics (HALO) furnished a Regulation FD update announcing it issued a statement on the final IPAY 2028 guidance for Medicare price negotiations from the U.S. Centers for Medicare & Medicaid Services.
Rhea-AI Filing Summary
Halozyme Therapeutics (HALO) furnished a Regulation FD update announcing it issued a statement on the final IPAY 2028 guidance for Medicare price negotiations from the U.S. Centers for Medicare & Medicaid Services. The statement includes the company’s long‑term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales. The statement is available on the company’s website and attached as Exhibit 99.1. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Halozyme (HALO) disclose in this 8-K?
Halozyme furnished a Regulation FD statement on final IPAY 2028 guidance for Medicare price negotiations, including long‑term projections related to Medicare Part B spend.
Where can I find Halozyme’s statement referenced in the 8-K?
The statement is available on the company’s corporate website and attached as Exhibit 99.1.
Does the 8-K say whether the information is filed or furnished?
It is furnished under Item 7.01 and is not deemed filed under Section 18, nor incorporated by reference into other filings.
What projections are mentioned for Halozyme (HALO)?
Long‑term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales.
What is the exhibit included with Halozyme’s 8-K?
Exhibit 99.1: Statement of Halozyme Therapeutics, Inc., dated October 14, 2025.
Which business area does the disclosure pertain to for Halozyme?
It pertains to ENHANZE partner products delivered subcutaneously and related Medicare Part B spending projections.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On October 14, 2025, Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), issued a statement (the “Statement”) on recently issued final IPAY 2028 guidance for Medicare price negotiations issued by the U.S. Centers for Medicare & Medicaid Services. The Statement includes the Company’s long-term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE® partner product subcutaneous sales. A copy of the Statement can be found on the Company’s corporate website and is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information set forth under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |||||||
99.1 | Statement of Halozyme Therapeutics, Inc., dated as of October 14, 2025 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc. (Registrant) | |||||||||||||||||
Dated: | October 14, 2025 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Senior Vice President, General Counsel and Corporate Secretary | |||||||||||||||||